AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,107 shares of the biotechnology company's stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc. owned 0.65% of AnaptysBio worth $2,610,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. grew its stake in shares of AnaptysBio by 191.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock worth $1,130,000 after buying an additional 22,164 shares in the last quarter. Victory Capital Management Inc. boosted its position in AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after buying an additional 97,200 shares during the period. Vanguard Group Inc. raised its holdings in shares of AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after purchasing an additional 143,584 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of AnaptysBio in the 4th quarter valued at about $311,000. Finally, AlphaQuest LLC raised its holdings in shares of AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 4,237 shares in the last quarter.

AnaptysBio Price Performance

Shares of ANAB stock traded down $0.30 during trading on Friday, reaching $20.44. The company's stock had a trading volume of 357,651 shares, compared to its average volume of 602,268. The company has a market capitalization of $600.53 million, a price-to-earnings ratio of -3.36 and a beta of -0.20. The stock's 50-day moving average price is $19.36 and its 200 day moving average price is $18.23. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million during the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has approved a stock repurchase program on Monday, March 24th that permits the company to buyback $75.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms recently commented on ANAB. Wells Fargo & Company boosted their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Wolfe Research started coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective on the stock. Johnson Rice reaffirmed a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Guggenheim increased their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.